Skip to main content
SpringerLink
Log in

Nanomedicine Applications in Cancer Treatment

  • Living reference work entry
  • First Online:
Handbook of Cancer and Immunology

  • 63 Accesses

Abstract

Despite all the advances made, cancer continues to be one of the main pathologies, responsible for almost ten million deaths worldwide in 2020, being lung cancer, colon cancer, liver cancer, stomach cancer, and breast cancer the main five neoplasms responsible for these deaths. In all these tumors, chemotherapy is one of the main therapeutic strategies, especially in advanced stages of the disease and when tumor cells have invaded other tissues and have metastasized. However, current antineoplastics are, in general, highly toxic which limits their dose and, therefore, their efficacy. In addition, many are poorly soluble in water, making them difficult to administer and requiring the use of organic solubilizing agents which increase the toxicity. In this sense, the use of nanocarriers can solve these problems and improve conventional chemotherapeutic treatments. On the one hand, these systems, in general, reduce the toxicity of these antineoplastics, since they tend to accumulate in the tumors, limiting the access of free drug to other tissues which allow the administration of higher doses. In addition, they allow the administration of very lipid-soluble antineoplastics without using these solubilizing agents. On the other hand, due to this selective accumulation, greater efficiency could also be obtained. This chapter discusses the nanoformulations that are currently approved or under clinical research for the treament of the main life-threatening tumors, indicating their advantages and disadvantages over conventional treatments, and underlying challenges of their clinical translation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  • Aggarwal C, Cohen RB, Yu E, Hwang W-T, Bauml JM, Alley E, Evans TL, Langer CJ (2018) Etirinotecan Pegol (NKTR-102) in third-line treatment of patients with metastatic or recurrent non–small-cell lung cancer: results of a phase II study. Clin Lung Cancer 19:157–162

    Article  CAS  Google Scholar 

  • Ahn HK, Jung M, Sym SJ, Shin DB, Kang SM, Kyung SY, Park JW, Jeong SH, Cho EK (2014) A phase II trial of Cremophor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 74:277–282

    Article  CAS  Google Scholar 

  • Anwanwan D, Singh SK, Singh S, Saikam V, Singh R (2020) Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer 1873:188314–188314

    Article  CAS  Google Scholar 

  • Awada A, Bondarenko IN, Bonneterre J, Nowara E, Ferrero JM, Bakshi AV, Wilke C, Piccart M (2014) A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). Ann Oncol 25:824–831

    Article  CAS  Google Scholar 

  • Banerji U, Van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, De Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P (2019) Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 20:1124–1135

    Article  CAS  Google Scholar 

  • Bardhi E, Marchetti C, Scopelliti A, Musacchio L, Tomao F, Schiavi M, Carraro C, Palaia I, Monti M, Muzii L, Benedetti Panici P (2019) Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer. Expert Opin Investig Drugs 28:667–673

    Article  CAS  Google Scholar 

  • Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamilton E, Sharma P, Recalde S, Gil EC, Traina T, O'shaughnessy J, Cortes J, Tsai M, Vahdat L, Diéras V, Carey LA, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Hurvitz SA (2021) Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol 32:1148–1156

    Article  CAS  Google Scholar 

  • Bernabeu E, Cagel M, Lagomarsino E, Moretton M, Chiappetta DA (2017) Paclitaxel: what has been done and the challenges remain ahead. Int J Pharm 526:474–495

    Article  CAS  Google Scholar 

  • Bhagat A, Kleinerman ES (2020) Anthracycline-induced cardiotoxicity: causes, mechanisms, and prevention. In: Kleinerman ES, Gorlick R (eds) Current advances in Osteosarcoma: clinical perspectives: past, present and future. Springer, Cham

    Google Scholar 

  • C de S L Oliveira AL, Schomann T, de Geus-Oei L-F, Kapiteijn E, Cruz LJ, de Araújo Junior RF (2021) Nanocarriers as a tool for the treatment of colorectal cancer. Pharmaceutics 13:1321

    Article  Google Scholar 

  • Chen H, Dy G, Groman A, Brady W, Jamshed S, Bushunow P, Brunsing N, Adjei A (2017a) P1.07-001 A phase II study of Etirinotecan Pegol (NKTR-102), a topoisomerase-I inhibitor polymer conjugate, in small cell lung cancer: topic: drug treatment alone and in combination with radiotherapy. J Thorac Oncol 12:S695–S696

    Article  Google Scholar 

  • Chen H, Dy G, Groman A, Farrell E, Miller A, Bushunow P, Adjei A (2017b) MA 01.06 A phase II study of Etirinotecan Pegol (NKTR-102) in patients with chemotherapy-resistant small cell lung cancer. J Thorac Oncol 12:S1800–S1801

    Article  Google Scholar 

  • Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, Krop IE, Blackwell K, Hoersch S, Xu J, Green M, Gianni L (2017) Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 18:732–742

    Article  Google Scholar 

  • Farooq MA, Aquib M, Farooq A, Haleem Khan D, Joelle Maviah MB, Sied Filli M, Kesse S, Boakye-Yiadom KO, Mavlyanova R, Parveen A, Wang B (2019) Recent progress in nanotechnology-based novel drug delivery systems in designing of cisplatin for cancer therapy: an overview. Artif Cells Nanomed Biotechnol 47:1674–1692

    Article  CAS  Google Scholar 

  • Fraguas-Sánchez AI, Martín-Sabroso C, Fernández-Carballido A, Torres-Suárez AI (2019) Current status of nanomedicine in the chemotherapy of breast cancer. Cancer Chemother Pharmacol 84:689–706

    Article  Google Scholar 

  • Fraguas-Sánchez AI, Lozza I, Torres-Suárez AI (2022) Actively targeted nanomedicines in breast cancer: from pre-Clinal investigation to clinic. Cancers 14:1198

    Article  Google Scholar 

  • Frampton JE (2020) Liposomal irinotecan: A review in metastatic pancreatic adenocarcinoma. Drugs 80:1007–1018

    Article  CAS  Google Scholar 

  • Fujiwara Y, Mukai H, Saeki T, Ro J, Lin Y-C, Nagai SE, Lee KS, Watanabe J, Ohtani S, Kim SB, Kuroi K, Tsugawa K, Tokuda Y, Iwata H, Park YH, Yang Y, Nambu Y (2019) A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. Br J Cancer 120:475–480

    Article  CAS  Google Scholar 

  • Gagliardi A, Giuliano E, Venkateswararao E, Fresta M, Bulotta S, Awasthi V, Cosco D (2021) Biodegradable polymeric nanoparticles for drug delivery to solid tumors. Front Pharmacol 12

    Google Scholar 

  • Ghanbari-Movahed M, Kaceli T, Mondal A, Farzaei MH, Bishayee A (2021) Recent advances in improved anticancer efficacies of Camptothecin nano-formulations: a systematic review. Biomedicines 9:9

    Article  Google Scholar 

  • Ghosh S (2019) Cisplatin: the first metal based anticancer drug. Bioorg Chem 88:102925

    Article  CAS  Google Scholar 

  • Giodini L, Re FL, Campagnol D, Marangon E, Posocco B, Dreussi E, Toffoli G (2017) Nanocarriers in cancer clinical practice: a pharmacokinetic issue. Nanomedicine 13:583–599

    Article  CAS  Google Scholar 

  • He H, Liu L, Morin EE, Liu M, Schwendeman A (2019) Survey of clinical translation of cancer nanomedicines-lessons learned from successes and failures. Acc Chem Res 52:2445–2461

    Article  CAS  Google Scholar 

  • Hennenfent KL, Govindan R (2006) Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol 17:735–749

    Article  CAS  Google Scholar 

  • Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D (2018) Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 19:115–126

    Article  CAS  Google Scholar 

  • Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Fasching PA, Afenjar K, Spera G, Lopez-Valverde V, Song C, Trask P, Boulet T, Sparano JA, Symmans WF, Thompson AM, Slamon D (2019) Neoadjuvant Trastuzumab Emtansine and Pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE study. J Clin Oncol 37:2206–2216

    Article  CAS  Google Scholar 

  • Jain MM, Gupte SU, Patil SG, Pathak AB, Deshmukh CD, Bhatt N, Haritha C, Govind Babu K, Bondarde SA, Digumarti R, Bajpai J, Kumar R, Bakshi AV, Bhattacharya GS, Patil P, Subramanian S, Vaid AK, Desai CJ, Khopade A, Chimote G, Bapsy PP, Bhowmik S (2016) Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study. Breast Cancer Res Treat 156:125–134

    Article  CAS  Google Scholar 

  • Jameson GS, Hamm JT, Weiss GJ, Alemany C, Anthony S, Basche M, Ramanathan RK, Borad MJ, Tibes R, Cohn A, Hinshaw I, Jotte R, Rosen LS, Hoch U, Eldon MA, Medve R, Schroeder K, White E, Von Hoff DD (2013) A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin Cancer Res 19:268–278

    Article  CAS  Google Scholar 

  • Johnston FM, Beckman M (2019) Updates on Management of Gastric Cancer. Curr Oncol Rep 21:67

    Article  Google Scholar 

  • Kang H, Rho S, Stiles WR, Hu S, Baek Y, Hwang DW, Kashiwagi S, Kim MS, Choi HS (2020) Size-dependent EPR effect of polymeric nanoparticles on tumor targeting. Adv Healthc Mater 9:e1901223

    Article  Google Scholar 

  • Kato K, Chin K, Yoshikawa T, Yamaguchi K, Tsuji Y, Esaki T, Sakai K, Kimura M, Hamaguchi T, Shimada Y, Matsumura Y, Ikeda R (2012) Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Investig New Drugs 30:1621–1627

    Article  CAS  Google Scholar 

  • Keam SJ (2020) Trastuzumab Deruxtecan: first approval. Drugs 80:501–508

    Article  CAS  Google Scholar 

  • Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J (2020) Antibody-drug conjugates: A comprehensive review. Mol Cancer Res 18:3–19

    Article  CAS  Google Scholar 

  • Kim TH, Gwak G, Chung MS, Kim JI, Park I, Um E, Han JW, Lee A (2018) Multicenter trial for safety and toxicity of a nanoparticle docetaxel formulation in breast cancer. Ann Oncol 29:ix3

    Article  Google Scholar 

  • Lee SY, Park HS, Lee KY, Kim HJ, Jeon YJ, Jang TW, Lee KH, Kim YC, Kim KS, Oh IJ, Kim SY (2013) Paclitaxel-loaded polymeric micelle (230 mg/m2) and cisplatin (60 mg/m2) vs. paclitaxel (175 mg/m2) and cisplatin (60 mg/m2) in advanced non–small-cell lung cancer: A multicenter randomized phase IIB trial. Clin Lung Cancer 14:275–282

    Article  CAS  Google Scholar 

  • Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, Lorusso PM, Munster PN, Campbell K, Gaddy DF, Leonard SC, Geretti E, Blocker SJ, Kirpotin DB, Moyo V, Wickham TJ, Hendriks BS (2017) (64)cu-MM-302 positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to treatment response in patients with metastatic breast cancer. Clin Cancer Res 23:4190–4202

    Article  CAS  Google Scholar 

  • Luo R, Li Y, He M, Zhang H, Yuan H, Johnson M, Palmisano M, Zhou S, Sun D (2017) Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations. Int J Pharm 519:1–10

    Article  CAS  Google Scholar 

  • Makoto, Nakao K, Fujita Y, Suzuki S, Arakawa Y, Sakai H, Sato H, Muramatsu (2020) (2020) Nab-paclitaxel Monotherapy for Relapsed Small Cell Lung Cancer: Retrospective Analysis and Review. Anticancer Res. 40(3):1579–1585 /anticanres/40/3/1579.atom 10.21873/anticanres.14105

    Google Scholar 

  • Martín-Sabroso C, Fraguas-Sánchez AI, Raposo-González R, Torres-Suárez AI (2021a) Perspectives in breast and ovarian cancer chemotherapy by nanomedicine approach: Nanoformulations in clinical research. Curr Med Chem 28:3271–3286

    Article  Google Scholar 

  • Martín-Sabroso C, Lozza I, Torres-Suárez AI, Fraguas-Sánchez AI (2021b) Antibody-antineoplastic conjugates in gynecological malignancies: current status and future perspectives. Pharmaceutics 13

    Google Scholar 

  • Martín-Sabroso C, Torres-Suárez AI, Alonso-González M, Fernández-Carballido A, Fraguas-Sánchez AI (2022) Active targeted Nanoformulations via folate receptors: state of the art and future perspectives. Pharmaceutics 14:14

    Article  Google Scholar 

  • Merle P, Camus P, Abergel A, Pageaux GP, Masliah C, Bronowicki JP, Zarski JP, Pelletier G, Bouattour M, Farloux L, Dorval E, Verset G, Si-Ahmed SN, Doffoel M, Couzigou P, Taieb J, Vasseur B, Attali P (2017) Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma. ESMO Open 2:e000238

    Article  Google Scholar 

  • Mohamed M, Abu Lila AS, Shimizu T, Alaaeldin E, Hussein A, Sarhan HA, Szebeni J, Ishida T (2019) PEGylated liposomes: immunological responses. Sci Technol Adv Mater 20:710–724

    Article  CAS  Google Scholar 

  • Munster P, Krop IE, Lorusso P, Ma C, Siegel BA, Shields AF, Molnár I, Wickham TJ, Reynolds J, Campbell K, Hendriks BS, Adiwijaya BS, Geretti E, Moyo V, Miller KD (2018) Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. Br J Cancer 119:1086–1093

    Article  CAS  Google Scholar 

  • Mylonakis N, Athanasiou A, Ziras N, Angel J, Rapti A, Lampaki S, Politis N, Karanikas C, Kosmas C (2010) Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer 68:240–247

    Article  CAS  Google Scholar 

  • Nardecchia S, Sánchez-Moreno P, De Vicente J, Marchal JA, Boulaiz H (2019) Clinical trials of thermosensitive nanomaterials: an overview. Nano 9

    Google Scholar 

  • Norouzi M, Hardy P (2021) Clinical applications of nanomedicines in lung cancer treatment. Acta Biomater 121:134–142

    Article  CAS  Google Scholar 

  • Olusanya TOB, Haj Ahmad RR, Ibegbu DM, Smith JR, Elkordy AA (2018) Liposomal drug delivery systems and anticancer drugs. Molecules 23

    Google Scholar 

  • Patravale V, Dandekar P, Jain R (2012) 6 - clinical trials industrial aspects. In: Patravale V, Dandekar P, Jain R (eds) Nanoparticulate drug delivery. Woodhead Publishing

    Chapter  Google Scholar 

  • Payne M, Ellis P, Dunlop D, Ranson M, Danson S, Schacter L, Talbot D (2006) DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial. J Thorac Oncol 1:984–990

    Article  Google Scholar 

  • Paz-Ares L, Ross H, O'brien M, Riviere A, Gatzemeier U, Von Pawel J, Kaukel E, Freitag L, Digel W, Bischoff H, García-Campelo R, Iannotti N, Reiterer P, Bover I, Prendiville J, Eisenfeld AJ, Oldham FB, Bandstra B, Singer JW, Bonomi P (2008) Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer 98:1608–1613

    Article  CAS  Google Scholar 

  • Perez EA, Awada A, O'shaughnessy J, Rugo HS, Twelves C, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Cortes J (2015) Etirinotecan pegol (NKTR-102) versus treatment of physician’s choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 16:1556–1568

    Article  CAS  Google Scholar 

  • Ranade AA, Joshi DA, Phadke GK, Patil PP, Kasbekar RB, Apte TG, Dasare RR, Mengde SD, Parikh PM, Bhattacharyya GS, Lopes GL (2013) Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India. Ann Oncol 24:v6–v12

    Article  Google Scholar 

  • Ravaioli A, Papi M, Pasquini E, Marangolo M, Rudnas B, Fantini M, Nicoletti SVL, Drudi F, Panzini I, Tamburini E, Gianni L, Pasini G (2009) Lipoplatin™ monotherapy: A phase II trial of second-line treatment of metastatic non-small-cell lung cancer. J Chemother 21:86–90

    Article  CAS  Google Scholar 

  • Rinnerthaler G, Gampenrieder SP, Greil R (2019) HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer. Int J Mol Sci 20

    Google Scholar 

  • Rudin CM, Brambilla E, Faivre-Finn C, Sage J (2021) Small-cell lung cancer. Nat Rev Dis Primers 7:3–3

    Article  Google Scholar 

  • Shigematsu H, Kadoya T, Masumoto N, Sasada T, Emi A, Ohara M, Kajitani K, Okada M (2015) The efficacy and safety of preoperative chemotherapy with triweekly abraxane and cyclophosphamide followed by 5-fluorouracil, epirubicin, and cyclophosphamide therapy for resectable breast cancer: a multicenter clinical trial. Clin Breast Cancer 15:110–116

    Article  CAS  Google Scholar 

  • Shitara K, Iwata H, Takahashi S, Tamura K, Park H, Modi S, Tsurutani J, Kadowaki S, Yamaguchi K, Iwasa S, Saito K, Fujisaki Y, Sugihara M, Shahidi J, Doi T (2019) Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol 20:827–836

    Article  CAS  Google Scholar 

  • Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF (2012) Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non–small-cell lung cancer: final results of a phase III trial. J Clin Oncol 30:2055–2062

    Article  CAS  Google Scholar 

  • Sofias AM, Dunne M, Storm G, Allen C (2017) The battle of “nano” paclitaxel. Adv Drug Deliv Rev 122:20–30

    Article  CAS  Google Scholar 

  • Stathopoulos GP, Boulikas T, Vougiouka M, Deliconstantinos G, Rigatos S, Darli E, Viliotou V, Stathopoulos JG (2005) Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. Oncol Rep 13:589–595

    CAS  Google Scholar 

  • Stathopoulos GP, Antoniou D, Dimitroulis J, Stathopoulos J, Marosis K, Michalopoulou P (2011) Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer. Cancer Chemother Pharmacol 68:945–950

    Article  CAS  Google Scholar 

  • Staudacher AH, Brown MP (2017) Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer 117:1736–1742

    Article  CAS  Google Scholar 

  • Sun A, Durocher-Allen LD, Ellis PM, Ung YC, Goffin JR, Ramchandar K, Darling G (2019) Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review. Curr Oncol (Toronto, Ont.) 26:e372–e384

    CAS  Google Scholar 

  • Taheri A, Rad A, Sadeghi E, Varshosaz J (2021) Comparison of efficacy and peripheral neuropathy of solvent-based paclitaxel with paclitaxel Poliglumex and NK105: A systematic review and Metaanalysis. Curr Pharm Des 27:2041–2055

    Article  CAS  Google Scholar 

  • Tahover E, Patil YP, Gabizon AA (2015) Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes. Anti-Cancer Drugs 26:241

    Article  CAS  Google Scholar 

  • Tak WY, Lin SM, Wang Y, Zheng J, Vecchione A, Park SY, Chen MH, Wong S, Xu R, Peng CY, Chiou YY, Huang GT, Cai J, Abdullah BJJ, Lee JS, Lee JY, Choi JY, Gopez-Cervantes J, Sherman M, Finn RS, Omata M, O’neal M, Makris L, Borys N, Poon R, Lencioni R (2018) Phase III HEAT study adding Lyso-thermosensitive liposomal doxorubicin to radiofrequency ablation in patients with Unresectable hepatocellular carcinoma lesions. Clin Cancer Res 24:73–83

    Article  CAS  Google Scholar 

  • Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Dieras V, Müller V, Tagliaferri M, Hannah AL, Cortés J (2019) ATTAIN: phase III study of etirinotecan pegol versus treatment of physician’s choice in patients with metastatic breast cancer and brain metastases. Future Oncol 15:2211–2225

    Article  CAS  Google Scholar 

  • Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kümmel S, Warm M, Fasching PA, Just M, Hanusch C, Hackmann J, Blohmer JU, Rhiem K, Schmitt WD, Furlanetto J, Gerber B, Huober J, Nekljudova V, VON Minckwitz G, Loibl S (2019) NAB-paclitaxel improves disease-free survival in early breast cancer: GBG 69-GeparSepto. J Clin Oncol 37:2226–2234

    Article  CAS  Google Scholar 

  • Waks AG, Winer EP (2019) Breast cancer treatment: a review. JAMA 321:288–300

    Article  CAS  Google Scholar 

  • Wang-Gillam A, Li C-P, Bodoky G, Dean A, Shan Y-S, Jameson G, Macarulla T, Lee K-H, Cunningham D, Blanc JF, Hubner RA, Chiu C-F, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen L-T, Adoo C, Anderson T, Asselah J, Azambuja A, Bampton C, Barrios CH, Bekaii-Saab T, Bohuslav M, Chang D, Chen J-S, Chen Y-C, Choi HJ, Chung IJ, Chung V, Csoszi T, Cubillo A, Demarco L, De Wit M, Dragovich T, Edenfield W, Fein LE, Franke F, Fuchs M, Gonzales-Cruz V, Gozza A, Fernando RH, Iaffaioli R, Jakesova J, Kahan Z, Karimi M, Kim JS, Korbenfeld E, Lang I, Lee F-C, Lee K-D, Lipton L, MA WW, Mangel L, Mena R, Palmer D, Pant S, Park JO, Piacentini P, Pelzer U, Plazas JG, Prasad C, Rau K-M, Raoul J-L, Richards D, Ross P, Schlittler L, Smakal M, Stahalova V, Sternberg C, Seufferlein T, Tebbutt N, Vinholes JJ, Wadlow R, Wenczl M, Wong M (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387:545–557

    Article  CAS  Google Scholar 

  • Werner ME, Cummings ND, Sethi M, Wang EC, Sukumar R, Moore DT, Wang AZ (2013) Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 86:463–468

    Article  CAS  Google Scholar 

  • Xu X, Wang L, Xu H-Q, Huang X-E, Qian Y-D, Xiang J (2013) Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pac J Cancer Prev 14:2591–2594

    Google Scholar 

  • Xu Y, Wang Y, Gong J, Zhang X, Peng Z, Sheng X, Mao C, Fan Q, Bai Y, Ba Y, Jiang D, Yang F, Qi C, Li J, Wang X, Zhou J, Lu M, Cao Y, Yuan J, Liu D, Wang Z, Fang J, Shen L (2021) Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer 24:913–925

    Article  CAS  Google Scholar 

  • Yang W, Lee J-C, Chen M-H, Zhang Z-Y, Bai X-M, Yin S-S, Cao K, Wang S, Wu W, Yan K (2019) Thermosensitive liposomal doxorubicin plus radiofrequency ablation increased tumor destruction and improved survival in patients with medium and large hepatocellular carcinoma: A randomized, double-blinded, dummy-controlled clinical trial in a single center. J Cancer Res Ther 15:773–783

    Article  CAS  Google Scholar 

  • Zahednezhad F, Zakeri-Milani P, Shahbazi Mojarrad J, Valizadeh H (2020) The latest advances of cisplatin liposomal formulations: essentials for preparation and analysis. Expert Opin Drug Deliv 17:523–541

    Article  CAS  Google Scholar 

  • Zeybek B, Manzano A, Bianchi A, Bonazzoli E, Bellone S, Buza N, Hui P, Lopez S, Perrone E, Manara P, Zammataro L, Altwerger G, Han C, Tymon-Rosario J, Menderes G, Ratner E, Silasi D-A, Huang GS, Azodi M, Schwartz PE, Santin A (2020) Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. Sci Rep 10:973

    Article  CAS  Google Scholar 

  • Zhang J, Pan Y, Shi Q, Zhang G, Jiang L, Dong X, Gu K, Wang H, Zhang X, Yang N, Li Y, Xiong J, Yi T, Peng M, Song Y, Fan Y, Cui J, Chen G, Tan W, Zang A, Guo Q, Zhao G, Wang Z, He J, Yao W, Wu X, Chen K, Hu X, Hu C, Yue L, Jiang D, Wang G, Liu J, Yu G, Li J, Bai J, Xie W, Zhao W, Wu L, Zhou C (2022) Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical study. Cancer Commun (Lond) 42:3–16

    Article  CAS  Google Scholar 

  • Zhao M, Li H, Fan L, Ma Y, Gong H, Lai W, Fang Q, Hu Z (2018) Quantitative proteomic analysis to the first commercialized liposomal paclitaxel nano-platform Lipusu revealed the molecular mechanism of the enhanced anti-tumor effect. Artif Cells Nanomed Biotechnol 46:S147–S155

    Article  Google Scholar 

  • Zhu L, Lin M (2021) The synthesis of nano-doxorubicin and its anticancer effect. Anti Cancer Agents Med Chem 21:2466–2477

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain

    Ana I. Fraguas-Sánchez, Cristina Martín-Sabroso, Irene Lozza & Ana I. Torres-Suárez

  2. Institute of Industrial Pharmacy, Complutense University of Madrid, Madrid, Spain

    Ana I. Fraguas-Sánchez, Cristina Martín-Sabroso & Ana I. Torres-Suárez

Authors
  1. Ana I. Fraguas-Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cristina Martín-Sabroso
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Irene Lozza
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ana I. Torres-Suárez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ana I. Torres-Suárez .

Editor information

Editors and Affiliations

  1. Division of Clinical Immunology, Karolinska University Hospital, Huddinge, Sweden

    Nima Rezaei

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Fraguas-Sánchez, A.I., Martín-Sabroso, C., Lozza, I., Torres-Suárez, A.I. (2023). Nanomedicine Applications in Cancer Treatment. In: Rezaei, N. (eds) Handbook of Cancer and Immunology. Springer, Cham. https://doi.org/10.1007/978-3-030-80962-1_294-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-80962-1_294-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-80962-1

  • Online ISBN: 978-3-030-80962-1

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation